niacinamide has been researched along with Cardiac Failure in 36 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined the hemodynamic parameters as well as femoral arterial and venous cyclic guanosine monophosphate (cGMP) concentrations during intravenous infusion of NTG or nicorandil, a nitrate and potassium channel opener, in patients with congestive heart failure." | 9.08 | Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. ( Fukai, D; Hisanaga, T; Kinoshita, M; Maeda, K; Maeda, Y; Tsutamoto, T; Wada, A; Yoshida, S, 1995) |
| "Twenty patients with congestive heart failure and pulmonary capillary wedge pressure (PCWP) > or = 18 mm Hg were randomly assigned to nitroglycerin or nicorandil in a double-blind, crossover study." | 9.08 | Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. ( Aarsland, T; Dickstein, K; Gøransson, L; Larsen, AI; Tamby, JF, 1997) |
| "To evaluate whether hemodynamic tolerance develops to nicorandil, a nitrate and potassium channel opener, 14 patients with chronic heart failure (CHF) were treated with nicorandil and 11 were treated with nitroglycerin (GTN)." | 9.07 | Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. ( Horie, H; Kinoshita, M; Maeda, Y; Nakae, I; Tsutamoto, T; Wada, A; Yabe, T, 1994) |
| "Rest and exercise hemodynamic and hormonal effects of nicorandil, a nicotinamide-nitrate vasodilator, were assessed in 9 patients with New York Heart Association class II or III congestive heart failure (CHF) and left ventricular ejection fraction less than or equal to 40%." | 9.06 | Usefulness of nicorandil in congestive heart failure. ( Binetti, G; Boriani, G; Boschi, S; Galié, N; Magnani, B; Maiello, L; Varani, E, 1990) |
| "Twenty-five patients with congestive heart failure (CHF) underwent a double-blind randomized study of the acute hemodynamic effects of orally administered nicorandil, a newly developed vasodilator drug." | 9.06 | Hemodynamic effects of oral nicorandil in congestive heart failure. ( Binkley, PF; Cody, RJ; Leier, CV; Moeschberger, ML; Mohrland, JS; Tice, FD; Wolf, DL, 1990) |
| "Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF)." | 7.70 | Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim. ( Koyama, T; Matsuzaki, T; Nakasone, J; Noguchi, K; Ojiri, Y; Sakanashi, M, 1998) |
| "Nicorandil is a nicotinamide derivative with a potential role in human therapeutics because of its potent vasodilating properties." | 6.67 | Clinical pharmacology of nicorandil in patients with congestive heart failure. ( Bindley, PF; Binkley, PF; Jungbluth, GL; Leier, CV; MacKichan, JJ; Mohrland, JS; Tice, FD; Wolf, DL, 1992) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | 6.45 | Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. ( Jarkowski, A; Wong, MK, 2009) |
| "Heart failure was produced by myocardial infarction, and was associated with markedly increased AMPK and SIRT1 protein levels." | 5.40 | Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. ( Gu, XS; Lei, JP; Li, L; Su, DF; Wang, ZB; Ye, Z; Zheng, X, 2014) |
| "Suddenly, he developed left cardiac failure, and he died 6 days later through a rapid clinical course that included circulatory failure, abnormal glucose tolerance, disseminated intravascular coagulation, and multiple organ failure." | 5.38 | [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. ( Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M, 2012) |
| "Nicorandil is a vasodilator drug that combines potassium channel opening properties with nitrate effects." | 5.28 | Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. ( Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992) |
| "Nicorandil is a new compound that has shown potent vasodilator activities on venous and arterial beds in experimental pharmacology." | 5.28 | Hemodynamic action of nicorandil in chronic congestive heart failure. ( Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989) |
| " We examined the hemodynamic parameters as well as femoral arterial and venous cyclic guanosine monophosphate (cGMP) concentrations during intravenous infusion of NTG or nicorandil, a nitrate and potassium channel opener, in patients with congestive heart failure." | 5.08 | Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. ( Fukai, D; Hisanaga, T; Kinoshita, M; Maeda, K; Maeda, Y; Tsutamoto, T; Wada, A; Yoshida, S, 1995) |
| "Twenty patients with congestive heart failure and pulmonary capillary wedge pressure (PCWP) > or = 18 mm Hg were randomly assigned to nitroglycerin or nicorandil in a double-blind, crossover study." | 5.08 | Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. ( Aarsland, T; Dickstein, K; Gøransson, L; Larsen, AI; Tamby, JF, 1997) |
| "To evaluate whether hemodynamic tolerance develops to nicorandil, a nitrate and potassium channel opener, 14 patients with chronic heart failure (CHF) were treated with nicorandil and 11 were treated with nitroglycerin (GTN)." | 5.07 | Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. ( Horie, H; Kinoshita, M; Maeda, Y; Nakae, I; Tsutamoto, T; Wada, A; Yabe, T, 1994) |
| "Rest and exercise hemodynamic and hormonal effects of nicorandil, a nicotinamide-nitrate vasodilator, were assessed in 9 patients with New York Heart Association class II or III congestive heart failure (CHF) and left ventricular ejection fraction less than or equal to 40%." | 5.06 | Usefulness of nicorandil in congestive heart failure. ( Binetti, G; Boriani, G; Boschi, S; Galié, N; Magnani, B; Maiello, L; Varani, E, 1990) |
| "Twenty-five patients with congestive heart failure (CHF) underwent a double-blind randomized study of the acute hemodynamic effects of orally administered nicorandil, a newly developed vasodilator drug." | 5.06 | Hemodynamic effects of oral nicorandil in congestive heart failure. ( Binkley, PF; Cody, RJ; Leier, CV; Moeschberger, ML; Mohrland, JS; Tice, FD; Wolf, DL, 1990) |
| "The data show that nicotinamide riboside, the most energy-efficient among NAD precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease with few therapeutic options." | 3.88 | Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. ( Baczkó, I; Blanc, J; Brenner, C; Breton, M; Decaux, JF; Deloux, R; Diguet, N; Garnier, A; Gouge, A; Gressette, M; Lavery, GG; Li, Z; Manoury, B; Mericskay, M; Mougenot, N; Piquereau, J; Tannous, C; Trammell, SAJ; Zoll, J, 2018) |
| "Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF)." | 3.70 | Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim. ( Koyama, T; Matsuzaki, T; Nakasone, J; Noguchi, K; Ojiri, Y; Sakanashi, M, 1998) |
| "Nicorandil is a nicotinamide derivative with a potential role in human therapeutics because of its potent vasodilating properties." | 2.67 | Clinical pharmacology of nicorandil in patients with congestive heart failure. ( Bindley, PF; Binkley, PF; Jungbluth, GL; Leier, CV; MacKichan, JJ; Mohrland, JS; Tice, FD; Wolf, DL, 1992) |
| "Treatment of breast cancer (BC) has changed over the last decade with the advent of targeted therapies." | 2.47 | Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. ( Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A, 2011) |
| "She received standard treatment for heart failure, including a beta-blocker, an angiotensin-converting enzyme inhibitor, and diuretics." | 2.45 | Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. ( Jarkowski, A; Wong, MK, 2009) |
| "Increasing use of targeted anticancer agents that inhibit tyrosine kinase signaling (monoclonal antibodies or tyrosine kinase inhibitors) has dramatically improved the survival of patients with malignancies." | 2.45 | Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. ( Chen, MH, 2009) |
| "Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases." | 1.46 | Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. ( Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H, 2017) |
| "Heart failure was produced by myocardial infarction, and was associated with markedly increased AMPK and SIRT1 protein levels." | 1.40 | Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. ( Gu, XS; Lei, JP; Li, L; Su, DF; Wang, ZB; Ye, Z; Zheng, X, 2014) |
| "Suddenly, he developed left cardiac failure, and he died 6 days later through a rapid clinical course that included circulatory failure, abnormal glucose tolerance, disseminated intravascular coagulation, and multiple organ failure." | 1.38 | [A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma]. ( Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M, 2012) |
| "DOX-induced heart failure is thought to be caused by reduction/oxidation cycling of DOX to generate oxidative stress and cardiomyocyte cell death." | 1.35 | Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. ( Bennett, JA; Danz, ED; Henry, N; Keller, RS; Skramsted, J, 2009) |
| "NCX is an attractive target for the treatment of heart failure and ischemia-reperfusion." | 1.33 | Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor. ( Kakefuda, A; Kuramochi, T; Sakamoto, S; Taguchi, T; Tsukamoto, I; Yamada, H, 2005) |
| "Nicorandil is a vasodilator drug that combines potassium channel opening properties with nitrate effects." | 1.28 | Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans. ( Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992) |
| "Nicorandil is a new compound that has shown potent vasodilator activities on venous and arterial beds in experimental pharmacology." | 1.28 | Hemodynamic action of nicorandil in chronic congestive heart failure. ( Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.67) | 18.7374 |
| 1990's | 10 (27.78) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, B | 1 |
| Wang, DD | 1 |
| Qiu, Y | 1 |
| Airhart, S | 1 |
| Liu, Y | 1 |
| Stempien-Otero, A | 1 |
| O'Brien, KD | 1 |
| Tian, R | 2 |
| Kimura, G | 1 |
| Kataoka, M | 1 |
| Inami, T | 1 |
| Fukuda, K | 1 |
| Yoshino, H | 1 |
| Satoh, T | 1 |
| Diguet, N | 1 |
| Trammell, SAJ | 1 |
| Tannous, C | 1 |
| Deloux, R | 1 |
| Piquereau, J | 1 |
| Mougenot, N | 2 |
| Gouge, A | 1 |
| Gressette, M | 1 |
| Manoury, B | 1 |
| Blanc, J | 1 |
| Breton, M | 1 |
| Decaux, JF | 1 |
| Lavery, GG | 1 |
| Baczkó, I | 1 |
| Zoll, J | 1 |
| Garnier, A | 1 |
| Li, Z | 1 |
| Brenner, C | 1 |
| Mericskay, M | 2 |
| Walker, MA | 1 |
| Vignier, N | 1 |
| Chatzifrangkeskou, M | 1 |
| Morales Rodriguez, B | 1 |
| Wahbi, K | 1 |
| Bonne, G | 1 |
| Muchir, A | 1 |
| Gu, XS | 1 |
| Wang, ZB | 1 |
| Ye, Z | 1 |
| Lei, JP | 1 |
| Li, L | 1 |
| Su, DF | 1 |
| Zheng, X | 1 |
| Pitoia, F | 1 |
| Ruan, Y | 1 |
| Dong, C | 1 |
| Patel, J | 1 |
| Duan, C | 1 |
| Wang, X | 1 |
| Wu, X | 1 |
| Cao, Y | 1 |
| Pu, L | 1 |
| Lu, D | 1 |
| Shen, T | 1 |
| Li, J | 1 |
| Haas, NB | 1 |
| Manola, J | 1 |
| Ky, B | 1 |
| Flaherty, KT | 1 |
| Uzzo, RG | 1 |
| Kane, CJ | 1 |
| Jewett, M | 1 |
| Wood, L | 1 |
| Wood, CG | 1 |
| Atkins, MB | 1 |
| Dutcher, JJ | 1 |
| Wilding, G | 1 |
| DiPaola, RS | 1 |
| Imran, TF | 1 |
| Shah, R | 1 |
| Ha, AS | 1 |
| Thomas, R | 1 |
| Joseph, J | 1 |
| ARCHI, G | 1 |
| TINACCI, F | 1 |
| Danz, ED | 1 |
| Skramsted, J | 1 |
| Henry, N | 1 |
| Bennett, JA | 1 |
| Keller, RS | 1 |
| Wong, MK | 1 |
| Jarkowski, A | 1 |
| Chen, MH | 1 |
| Livanov, GA | 1 |
| Amagyrov, VP | 1 |
| Batotsyrenov, BV | 1 |
| Lodiagin, AN | 1 |
| Batotsyrenova, KhV | 1 |
| Zambelli, A | 1 |
| Della Porta, MG | 1 |
| Eleuteri, E | 1 |
| De Giuli, L | 1 |
| Catalano, O | 1 |
| Tondini, C | 1 |
| Riccardi, A | 1 |
| Geisberg, C | 1 |
| Pentassuglia, L | 1 |
| Sawyer, DB | 1 |
| Kimura, T | 1 |
| Suetomi, T | 1 |
| Miyagawa, T | 1 |
| Tsutsumi, M | 1 |
| Rose, S | 1 |
| RE, A | 1 |
| Alcendor, RR | 1 |
| Kirshenbaum, LA | 1 |
| Imai, S | 1 |
| Vatner, SF | 1 |
| Sadoshima, J | 1 |
| Kuramochi, T | 1 |
| Kakefuda, A | 1 |
| Yamada, H | 1 |
| Tsukamoto, I | 1 |
| Taguchi, T | 1 |
| Sakamoto, S | 1 |
| Bachert, EL | 1 |
| Fung, HL | 1 |
| Tsutamoto, T | 2 |
| Kinoshita, M | 2 |
| Hisanaga, T | 1 |
| Maeda, Y | 2 |
| Maeda, K | 1 |
| Wada, A | 2 |
| Fukai, D | 1 |
| Yoshida, S | 1 |
| Nakae, I | 1 |
| Yabe, T | 1 |
| Horie, H | 1 |
| Satoh, K | 1 |
| Larsen, AI | 1 |
| Gøransson, L | 1 |
| Aarsland, T | 1 |
| Tamby, JF | 1 |
| Dickstein, K | 1 |
| Noguchi, K | 1 |
| Matsuzaki, T | 1 |
| Ojiri, Y | 1 |
| Koyama, T | 1 |
| Nakasone, J | 1 |
| Sakanashi, M | 1 |
| Giles, TD | 1 |
| Pina, IL | 1 |
| Quiroz, AC | 1 |
| Roffidal, L | 1 |
| Zaleski, R | 1 |
| Porter, RS | 1 |
| Karalis, DG | 1 |
| Mohrland, JS | 3 |
| Wolf, DL | 3 |
| Hearron, AE | 1 |
| Tice, FD | 2 |
| Jungbluth, GL | 1 |
| Binkley, PF | 2 |
| MacKichan, JJ | 1 |
| Leier, CV | 2 |
| Bindley, PF | 1 |
| Galié, N | 1 |
| Varani, E | 1 |
| Maiello, L | 1 |
| Boriani, G | 1 |
| Boschi, S | 1 |
| Binetti, G | 1 |
| Magnani, B | 1 |
| Cody, RJ | 1 |
| Moeschberger, ML | 1 |
| Solal, AC | 1 |
| Jaeger, P | 1 |
| Bouthier, J | 1 |
| Juliard, JM | 1 |
| Dahan, M | 1 |
| Gourgon, R | 1 |
| Nurmukhambetov, AN | 1 |
| Riabtseva, TA | 1 |
| Bosisio, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Preoperative Nicotinamide Riboside (Vitamin B3) Supplementation in Patients Undergoing Elective Left Ventricular Assist Device (LVAD) Implantation[NCT03727646] | Early Phase 1 | 5 participants (Actual) | Interventional | 2018-09-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Cardiac Failure
| Article | Year |
|---|---|
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2009 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agent | 2012 |
[Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
Topics: Animals; Benzopyrans; Calcium Channel Blockers; Cromakalim; Guanidines; Heart Failure; Hemodynamics; | 1993 |
8 trials available for niacinamide and Cardiac Failure
| Article | Year |
|---|---|
Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure.
Topics: Female; Heart Failure; Humans; Inflammation; Leukocytes, Mononuclear; Male; Mitochondria, Heart; Mod | 2020 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Ad | 2015 |
Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Cyclic GMP; Female; Heart Failure; Hemodynamics; | 1995 |
Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure.
Topics: Adult; Aged; Atrial Natriuretic Factor; Drug Tolerance; Female; Heart Failure; Hemodynamics; Humans; | 1994 |
Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure.
Topics: Aged; Cross-Over Studies; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Infusion | 1997 |
Clinical pharmacology of nicorandil in patients with congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Cardiovascular System; Double-Blind Method; | 1992 |
Usefulness of nicorandil in congestive heart failure.
Topics: Adult; Double-Blind Method; Exercise; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Ma | 1990 |
Hemodynamic effects of oral nicorandil in congestive heart failure.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; | 1990 |
23 other studies available for niacinamide and Cardiac Failure
| Article | Year |
|---|---|
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary H | 2017 |
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy.
Topics: Acrylamides; AMP-Activated Protein Kinases; Animals; Cardiomyopathy, Dilated; Citric Acid; Cytokines | 2018 |
Raising NAD in Heart Failure: Time to Translate?
Topics: Animals; Cardiomyopathy, Dilated; Heart Failure; Mice; NAD; Niacinamide; Pyridinium Compounds | 2018 |
Rescue of biosynthesis of nicotinamide adenine dinucleotide protects the heart in cardiomyopathy caused by lamin A/C gene mutation.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Heart; Heart Failure; Heart Ventricles; Humans; L | 2018 |
Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Cells, Cultured; Heart Failure; Male; Mice; Myoca | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; | 2014 |
SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways.
Topics: Animals; Apoptosis; Cell Line; Doxorubicin; Gene Expression Regulation; Heart Failure; Humans; Mice; | 2015 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niaci | 2016 |
On the action of nicotinic amide in the liver due to stasis (heart failure).
Topics: Heart Failure; Liver Diseases; Niacin; Niacinamide | 1948 |
Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway.
Topics: Animals; Cardiotonic Agents; Cell Death; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; | 2009 |
[Pharmacological correction of hypoxic and free-radical disorders in patients with acute myocardial infarction complicated by acute heart failure].
Topics: Acute Disease; Critical Care; Drug Combinations; Flavin Mononucleotide; Fluorocarbons; Free Radicals | 2010 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intole | 2012 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; H | 2013 |
[Combined adenosinetriphosphoric acid, cocarboxylase, vitamin B12 and nicotinamide in therapy of congestive heart failure; first clinical trials].
Topics: Adenosine Triphosphate; Corrinoids; Heart Failure; Hematinics; Humans; Niacin; Niacinamide; Nicotini | 1959 |
Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes.
Topics: Acetylation; Alkaloids; Animals; Apoptosis; Atrial Natriuretic Factor; Benzamides; Benzophenanthridi | 2004 |
Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Calcium; Calcium Channel Blockers; Cytochrom | 2005 |
Hemodynamic tolerance and pharmacokinetics of nicorandil in experimental heart failure.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Chromatography, High Pressure Liquid; Heart Failur | 1993 |
Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim.
Topics: Acute Disease; Animals; Blood Pressure; Coronary Circulation; Cromakalim; Disease Models, Animal; Do | 1998 |
Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Topics: Aged; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Female; Heart Failure; Heart Rate; | 1992 |
A symposium: A new treatment for angina pectoris and heart failure. October 17, 1987, San Francisco. Proceedings.
Topics: Angina Pectoris; Animals; Heart Failure; Humans; Niacinamide; Nicorandil; Vasodilator Agents | 1989 |
Hemodynamic action of nicorandil in chronic congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chronic Disease; Female; Heart Failure; Heart Rate; Hem | 1989 |
[Prevention of disorders of cardiac contractility with nicotinamide in adriblastin -related damage].
Topics: Animals; Cardiomyopathies; Doxorubicin; Heart Failure; Hypoxia; Myocardial Contraction; Niacinamide; | 1988 |
[Action of a new choleretic associated with a spasmolytic and with vitamin B 1 and vitamin PP in therapy of some hepato-biliary disease conditions].
Topics: Adult; Aged; Biliary Dyskinesia; Cholagogues and Choleretics; Female; Heart Failure; Humans; Male; M | 1967 |